Physicochemical Properties
| Molecular Formula | C17H18N6 |
| Molecular Weight | 306.37 |
| Appearance | Off-white to light yellow solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | 3-IN-PP1 shows significant pan-PKD inhibitory activity against PKD1, PKD2, and PKD3, with IC50 values of 108, 94, and 108 nM, respectively [1]. 3-IN-PP1 (5 μM, 0-114 h) has strong anti-proliferative activity on PANC-1 cells [1]. 3-IN-PP1 (20 μM, 1 h) significantly inhibits PKD-dependent cortactin phosphorylation in PANC-1 cells [1]. 3-IN-PP1 inhibits tumor cell proliferation at IC50 values ranging from 1.6 to 39.2μM [1]. |
| Cell Assay |
Cell Proliferation Assay[1] Cell Types: PANC-1 cell Tested Concentrations: 5 μM Incubation Duration: 0-114 h Experimental Results: Dramatically inhibited PANC-1 cell proliferation after incubation for 96 and 144 hrs (hours). Western Blot Analysis[1] Cell Types: PANC-1 cells Tested Concentrations: 20 μM Incubation Duration: 1 h Experimental Results: decreased cortactin phosphorylation in PANC-1 cells. |
| References |
[1]. Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyrimidine-based protein kinase D inhibitors. Eur J Med Chem. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2640 mL | 16.3201 mL | 32.6403 mL | |
| 5 mM | 0.6528 mL | 3.2640 mL | 6.5281 mL | |
| 10 mM | 0.3264 mL | 1.6320 mL | 3.2640 mL |